Correction: Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: A phase I study (Clinical Cancer Research (2009) 15, (5584-5590))

C. H. Mom; J. Verweij; C. N A M Oldenhuis

doi:https://doi.org/10.1158/1078-0432.CCR-15-21-COR1

Correction: Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: A phase I study (Clinical Cancer Research (2009) 15, (5584-5590))

C. H. Mom, J. Verweij, C. N A M Oldenhuis

Research output: Contribution to journal › Comment/Letter to the editor › Academic

2 Citations (Scopus)

Original language	English
Number of pages	1
Journal	Clinical Cancer Research
Volume	15
Issue number	21
DOIs	https://doi.org/10.1158/1078-0432.CCR-15-21-COR1
Publication status	Published - 1 Nov 2009

Access to Document

https://doi.org/10.1158/1078-0432.CCR-15-21-COR1

Cite this

@article{aaab790a676a4e2b9b8a5f913d5ce716,

title = "Correction: Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: A phase I study (Clinical Cancer Research (2009) 15, (5584-5590))",

author = "Mom, {C. H.} and J. Verweij and Oldenhuis, {C. N A M}",

year = "2009",

month = nov,

day = "1",

doi = "https://doi.org/10.1158/1078-0432.CCR-15-21-COR1",

language = "English",

volume = "15",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "21",

}

Correction: Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: A phase I study (Clinical Cancer Research (2009) 15, (5584-5590)). / Mom, C. H.; Verweij, J.; Oldenhuis, C. N A M.
In: Clinical Cancer Research, Vol. 15, No. 21, 01.11.2009.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

TY - JOUR

T1 - Correction

T2 - Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: A phase I study (Clinical Cancer Research (2009) 15, (5584-5590))

AU - Mom, C. H.

AU - Verweij, J.

AU - Oldenhuis, C. N A M

PY - 2009/11/1

Y1 - 2009/11/1

UR - http://www.scopus.com/inward/record.url?scp=70350704803&partnerID=8YFLogxK

U2 - https://doi.org/10.1158/1078-0432.CCR-15-21-COR1

DO - https://doi.org/10.1158/1078-0432.CCR-15-21-COR1

M3 - Comment/Letter to the editor

SN - 1078-0432

VL - 15

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 21

ER -

Correction: Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: A phase I study (Clinical Cancer Research (2009) 15, (5584-5590))

Access to Document

Other files and links

Cite this